v3.26.1
Note 9 - Segment Information
12 Months Ended
Apr. 30, 2026
Notes to Financial Statements  
Segment Reporting [Text Block]

Note 9 - Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM in deciding how to allocate resources and in assessing performance. The Company has determined that its CODM is its Chief Executive Officer.

 

Management and the CODM view the Company’s operations and manage its business in one operating segment, which is the business of identifying, developing and commercializing products and AI-ECG solutions in the cardiovascular diagnostic technology field. The CODM uses operating expenses to measure performance against progress in its clinical trials and its product development. The Company's CODM reviews and evaluates the total net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods.

 

The following table summarizes the segment's financial information including the Company's significant segment expenses:

 

  

April 30,

  

April 30,

 
  

2026

  

2025

 
         

Gross Margin

 $2,551  $2,470 

Segment operating expenses:

        

Clinical and regulatory

  644,157   756,189 

Research and development

  2,025,445   3,456,312 

Sales and marketing

  616,323   350,167 

Operations

  169,410   173,604 

General and administrative

  4,960,083   3,618,769 

Loss from operations

  (8,412,867)  (8,352,571)

Interest expense

  753,041   500,453 

Other income

  (24,033)  (87,795)

Total other expense

  729,008   412,658 

Net loss

 $(9,141,875) $(8,765,229)